| abstract |
Enantiomer (-) of tenatoprazole, or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazo[4,5-b]pyridine, or one of its salts, substantially free of the (+) enantiomer is disclosed. These (-) enantiomers of tenatoprazole exhibits improved pharmacokinetic properties which make it possible to use a once a day posology of a drug for relevant indications, and they can be used for curing digestive pathologies. |